efineptakin alfa

Home
Ligands
efineptakin alfa

GtoPdb Ligand ID: 11097

Compound class: Peptide or derivative

Comment: Efineptakin alfa is a long-acting immunoglobulin (Ig) fusion protein composed of recombinant human IL-7 fused to a hybrid Fc (hyFc) region of a human antibody. It comprises two disulphide bond-linked peptide chains. Efineptakin alfa has hematopoietic and immunopotentiating activities. In the oncology setting IL-7 enhances T-cell-mediated anti-tumour immune responses. Efineptakin alfa is being developed by Genexine (in-licensed to I-MAB Biopharma) and NeoImmuneTech. The peptide sequence of efineptakin alfa is claimed in Genexine's patent WO2016200219A1 as sequence 24 and would appear to be referred to as MGM-IL-7-hyFc therein [3].

Immunopharmacology Comments
Efineptakin alfa (Hyleukin-7^TM, research code NT-I7), is engineered to induce a persistent and long-lasting anti-tumour T cell response. It acts at multiple levels of T cell development and enhances T cell production, maturation, expansion, and survival, and also improves T cell homing and tumour infiltration. The Fc portion of the fusion protein extends the protein's half-life, and is IgD and IgG4-based so does not induce ADCC or CDC reactions.

Immunopharmacology Comments

Efineptakin alfa (Hyleukin-7^TM, research code NT-I7), is engineered to induce a persistent and long-lasting anti-tumour T cell response. It acts at multiple levels of T cell development and enhances T cell production, maturation, expansion, and survival, and also improves T cell homing and tumour infiltration. The Fc portion of the fusion protein extends the protein's half-life, and is IgD and IgG4-based so does not induce ADCC or CDC reactions.